Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) FCF Margin (2022 - 2025)

Historic FCF Margin for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to 28.57%.

  • Phathom Pharmaceuticals' FCF Margin rose 3604800.0% to 28.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 153.12%, marking a year-over-year increase of 7898400.0%. This contributed to the annual value of 483.07% for FY2024, which is 199295400.0% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported FCF Margin of 28.57% as of Q3 2025, which was up 3604800.0% from 158.98% recorded in Q2 2025.
  • Over the past 5 years, Phathom Pharmaceuticals' FCF Margin peaked at 1626.57% during Q1 2022, and registered a low of 6491.5% during Q4 2023.
  • Over the past 4 years, Phathom Pharmaceuticals' median FCF Margin value was 186.45% (recorded in 2024), while the average stood at 771.71%.
  • Per our database at Business Quant, Phathom Pharmaceuticals' FCF Margin tumbled by -69232100bps in 2023 and then skyrocketed by 62775600bps in 2024.
  • Phathom Pharmaceuticals' FCF Margin (Quarter) stood at 431.71% in 2022, then plummeted by -1604bps to 6491.5% in 2023, then surged by 97bps to 213.93% in 2024, then soared by 87bps to 28.57% in 2025.
  • Its FCF Margin stands at 28.57% for Q3 2025, versus 158.98% for Q2 2025 and 297.96% for Q1 2025.